Physician profile
Jon Mann
NPI 1477651479
$547.66
in general payments reported to CMS, 2019-2025
10 companies · $14.66 in 2025
The $14.66 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $95.45 · 2022: $50.96 · 2023: $86.69 · 2024: $41.31 · 2025: $14.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $110.35 | 2020-2024 | Tezspire |
| E.R. Squibb & Sons, L.L.C. | $94.96 | 2019 | |
| Mylan Specialty L.P. | $82.17 | 2019 | |
| Glaxosmithkline, LLC. | $81.46 | 2019 | |
| Electromed, INC. | $61.75 | 2023-2024 | Smartvest |
| Genzyme Corporation | $32.87 | 2023 | |
| Phadia US INC. | $31.43 | 2022 | |
| Insmed, INC. | $19.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.48 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Verona Pharma, INC. | $14.66 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.